Key facts
- This page summarizes Vikram Karnani's Form 4 filing for Dyne Therapeutics, Inc. (DYN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 23 Dec 2025, 16:08.
Vikram Karnani - 22 Dec 2025 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)
- Reporting relationship
- Director
- Issuer ticker
- DYN
- Reported as of
- 22 Dec 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Dec 2025, 16:08:03 UTC
- Prior SEC filing
- 14 Nov 2025
- Next SEC filing
- 12 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ron Caponigro, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Vikram Karnani filed Form 4 for Dyne Therapeutics, Inc. (DYN) on 23 Dec 2025.
Change
- Previous filing in this sequence was filed on 14 Nov 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001699488
Primary reporting owner
Karnani Vikram
- Relationship
- Director
- Address
- 1560 TRAPELO ROAD, WALTHAM
- Signature
- /s/ Ron Caponigro, Attorney-in-Fact
- Signature date
- 23 Dec 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DYN
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +59,665
- Change %
- Price
- $0.000000
- Shares after
- 59,665
- Date
- 22 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 59,665
- Exercise price
- $20.78
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option was granted on December 22, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments through December 22, 2028.